Novacyt S.A.
- Jurisdiction
France - LEI
213800BWAC2BF295EG28 - ISIN
FR0010397232 (ALNOV.PA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. Read full profile
Fundamentals
- Net revenue
€16.86M - Gross margin
11.9% - EBIT
-€26.55M - EBIT margin
-157.5% - Net income
-€44.89M - Net margin
-266.3%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 2, 2025 (Q4 2024)